Kjersti Flatmark

• Ree, Anne Hansen; Saltyte Benth, Jurate; Hamre, Hanne Mari; Kersten, Christian; Hofsli, Eva & Guren, Marianne [Vis alle 14 forfattere av denne artikkelen] (2024). First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer—the randomised METIMMOX trial. British Journal of Cancer. ISSN 0007-0920. doi: 10.1038/s41416-024-02696-6.
• Nygaard, Vigdis; Ree, Anne Hansen; Dagenborg, Vegar Johansen; Børresen-Dale, Anne-Lise; Edwin, Bjørn von Gohren & Fretland, Åsmund Avdem [Vis alle 10 forfattere av denne artikkelen] (2023). A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases. Cancer Research Communications. ISSN 2767-9764. 3(2), s. 235–244. doi: 10.1158/2767-9764.CRC-22-0295. Fulltekst i vitenarkiv
• Ito, Ichiaki; Abdelrahman M.G.Yousef, Abdelrahman M.G.; Chowdhury, Saikat; Dickson, Princess N.; Naini, Zahra A. & White, Michael G. [Vis alle 11 forfattere av denne artikkelen] (2023). Intraperitoneal Paclitaxel Is a Safe and Effective Therapeutic Strategy for Treating Mucinous Appendiceal Adenocarcinoma. Cancer Research. ISSN 0008-5472. 83(19), s. 3184–3191. doi: 10.1158/0008-5472.CAN-23-0013.
• Thorgersen, Ebbe Billmann; Solbakken, Arne Mide; Strøm, Tuva Kristine; Goscinski, Mariusz Adam; Spasojevic, Milan & Larsen, Stein Gunnar [Vis alle 7 forfattere av denne artikkelen] (2023). Short-term results after robot-assisted surgery for primary rectal cancers requiring beyond total mesorectal excision in multiple compartments. Scandinavian Journal of Surgery. ISSN 1457-4969. doi: 10.1177/14574969231200654. Fulltekst i vitenarkiv
• Solbakken, Arne Mide; Sellevold, Simen; Spasojevic, Milan; Julsrud, Lars; Emblemsvåg, Hanne-Line & Reims, Henrik Mikael [Vis alle 14 forfattere av denne artikkelen] (2023). Navigation-Assisted Surgery for Locally Advanced Primary and Recurrent Rectal Cancer. Annals of Surgical Oncology. ISSN 1068-9265. 30. doi: 10.1245/s10434-023-13964-9. Fulltekst i vitenarkiv
• Arjona-Sanchez, A.; Martinez-López, A.; Moreno-Montilla, M.T.; Mulsow, J.; Lozano-Lominchar, P. & Martínez-Torres, B. [Vis alle 50 forfattere av denne artikkelen] (2023). External multicentre validation of pseudomyxoma peritonei PSOGI-Ki67 classification. European Journal of Surgical Oncology. ISSN 0748-7983. 49(8), s. 1481–1488. doi: 10.1016/j.ejso.2023.03.206.
• Høye, Eirik; Dagenborg, Vegar Johansen; Kristensen, Annette Torgunrud; Lund-Andersen, Christin; Fretland, Åsmund Avdem & Lorenz, Susanne [Vis alle 13 forfattere av denne artikkelen] (2023). T cell receptor repertoire sequencing reveals chemotherapy-driven clonal expansion in colorectal liver metastases. GigaScience. ISSN 2047-217X. 12. doi: 10.1093/gigascience/giad032. Fulltekst i vitenarkiv
• Hyldbakk, Astrid; Fleten, Karianne Giller; Snipstad, Sofie; Åslund, Andreas; Davies, Catharina de Lange & Flatmark, Kjersti [Vis alle 7 forfattere av denne artikkelen] (2023). Intraperitoneal administration of cabazitaxel-loaded nanoparticles in peritoneal metastasis models. Nanomedicine: Nanotechnology, Biology and Medicine. ISSN 1549-9634. 48, s. 1–11. doi: 10.1016/j.nano.2023.102656. Fulltekst i vitenarkiv Vis sammendrag

  Colorectal and ovarian cancers frequently develop peritoneal metastases with few treatment options. Intraperitoneal chemotherapy has shown promising therapeutic effects, but is limited by rapid drug clearance and systemic toxicity. We therefore encapsulated the cabazitaxel taxane in poly(alkyl cyanoacrylate) (PACA) nanoparticles (NPs), designed to improve intraperitoneal delivery. Toxicity of free and encapsulated cabazitaxel was investigated in rats by monitoring clinical signs, organ weight and blood hematological and biochemical parameters. Pharmacokinetics, biodistribution and treatment response were evaluated in mice. Biodistribution was investigated by measuring both cabazitaxel and the 2-ethylbutanol NP degradation product. Drug encapsulation was shown to increase intraperitoneal drug retention, leading to prolonged intraperitoneal drug residence time and higher drug concentrations in peritoneal tumors. As a result, encapsulation of cabazitaxel improved the treatment response in two in vivo models bearing intraperitoneal tumors. Together, these observations indicate a strong therapeutic potential of NP-based cabazitaxel encapsulation as a novel treatment for peritoneal metastases.

• Patrick-Brown, Dawn Judith; Mohamed, Faheez; Thrower, Andrew; Kristensen, Annette Torgunrud; Cosyns, Sarah & Canbay, Emel [Vis alle 9 forfattere av denne artikkelen] (2023). Determining a minimum data set for reporting clinical and radiologic data for pseudomyxoma peritonei. Pleura and Peritoneum. ISSN 2364-7671. 8(1), s. 1–9. doi: 10.1515/pp-2022-0200. Fulltekst i vitenarkiv
• Larsen, Stein Gunnar; Goscinski, Mariusz Adam; Dueland, Svein; Steigen, Sonja Eriksson; Hofsli, Eva & Kristensen, Annette Torgunrud [Vis alle 10 forfattere av denne artikkelen] (2022). Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients. British Journal of Cancer. ISSN 0007-0920. s. 726–735. doi: 10.1938/s41416-021-01620-6.
• Fleten, Karianne Giller; Hyldbakk, Astrid; Einen, Caroline; Benjakul, Sopisa; Strand, Berit Løkensgard & Davies, Catharina de Lange [Vis alle 8 forfattere av denne artikkelen] (2022). Alginate Microsphere Encapsulation of Drug-Loaded Nanoparticles: A Novel Strategy for Intraperitoneal Drug Delivery. Marine Drugs. ISSN 1660-3397. 20(12). doi: 10.3390/md20120744. Fulltekst i vitenarkiv Vis sammendrag

  Alginate hydrogels have been broadly investigated for use in medical applications due to their biocompatibility and the possibility to encapsulate cells, proteins, and drugs. In the treatment of peritoneal metastasis, rapid drug clearance from the peritoneal cavity is a major challenge. Aiming to delay drug absorption and reduce toxic side effects, cabazitaxel (CAB)-loaded poly(alkyl cyanoacrylate) (PACA) nanoparticles were encapsulated in alginate microspheres. The PACAlg alginate microspheres were synthesized by electrostatic droplet generation and the physicochemical properties, stability, drug release kinetics, and mesothelial cytotoxicity were analyzed before biodistribution and therapeutic efficacy were studied in mice. The 450 µm microspheres were stable at in vivo conditions for at least 21 days after intraperitoneal implantation in mice, and distributed evenly throughout the peritoneal cavity without aggregation or adhesion. The nanoparticles were stably retained in the alginate microspheres, and nanoparticle toxicity to mesothelial cells was reduced, while the therapeutic efficacy of free CAB was maintained or improved in vivo. Altogether, this work presents the alginate encapsulation of drug-loaded nanoparticles as a promising novel strategy for the treatment of peritoneal metastasis that can improve the therapeutic ratio between toxicity and therapeutic efficacy.

• Høye, Eirik; Fromm, Bastian; Böttger, Paul H.M.; Domanska, Diana; Kristensen, Annette Torgunrud & Lund-Andersen, Christin [Vis alle 13 forfattere av denne artikkelen] (2022). A comprehensive framework for analysis of microRNA sequencing data in metastatic colorectal cancer. NAR Cancer. ISSN 2632-8674. 4(1), s. 1–13. doi: 10.1093/narcan/zcab051. Fulltekst i vitenarkiv
• Meltzer, Sebastian; Negård, Anne; Bakke, Kine Mari; Hamre, Hanne Mari; Kersten, Christian & Hofsli, Eva [Vis alle 10 forfattere av denne artikkelen] (2022). Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer. British Journal of Cancer. ISSN 0007-0920. 127, s. 2227–2233. doi: 10.1038/s41416-022-02004-0. Fulltekst i vitenarkiv
• Ree, Anne Hansen; Mælandsmo, Gunhild Mari; Flatmark, Kjersti; Russnes, Hege Elisabeth Giercksky; Casteneda, Monica Gomez & Aas, Eline (2022). Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer – the MetAction precision medicine study. Acta Oncologica. ISSN 0284-186X. 61(8), s. 955–962. doi: 10.1080/0284186X.2022.2098053. Fulltekst i vitenarkiv
• Ambrosini, Margherita; Del Re, Marzia; Manca, Paolo; Hendifar, Andrew; Drilon, Alexander & Harada, Guilherme [Vis alle 21 forfattere av denne artikkelen] (2022). ALK Inhibitors in Patients with ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series. JCO Precision Oncology (JCO PO). 6(1). doi: 10.1200/PO.22.00015. Fulltekst i vitenarkiv Vis sammendrag

  PURPOSE In GI cancers, anaplastic lymphoma kinase (ALK) rearrangements are extremely less frequent than in non–small-cell lung cancer but may be important to offer personalized strategies of treatment in selected patients. Data about the activity and efficacy of ALK inhibitors (ALKi) in GI cancers are scarce. MATERIALS AND METHODS We assembled a clinical and molecular international data set of pretreated patients with metastatic or nonresectable cancers of GI primary tumor origin with documented ALK rearrangement treated with at least one line of ALKi. Measurable disease as per RECIST 1.1 was required for response analysis. RESULTS Primary tumor sites were distributed as follows: 5 (38%) pancreas, 3 (23%) right colon, and 1 (8%) for each one of gastric, duodenal, rectal, left colon, and biliary tract sites. Seven patients (54%) were treated with alectinib, 5 (38%) with crizotinib, and 1 (8%) with entrectinib. After disease progression, five patients (38%) received a subsequent ALKi treatment line, and at the time of data cutoff date, treatment was still ongoing in two patients. Five of 12 evaluable patients (41%) achieved a partial response to first-line ALKi, five patients (41%) had stable disease, and 2 (17%) had progressive disease. No complete responses were registered. At a median follow-up of 39.6 months (interquartile range: 19.8-59.5), the median progression-free survival was 5.0 months (95% CI, 3.68 to no response) and the median overall survival was 9.3 months (95% CI, 5.46 to no response). CONCLUSION Treatment with ALKi provides remarkable responses and clinical benefit in pretreated patients with ALK fusion–positive GI malignancies. Despite the rarity, ALK rearrangements represent an important therapeutic target in individual pretreated patients with GI solid tumors. Further work providing prospective clinical validation of this target is needed.

• Fleten, Karianne Giller; Eksteen, Jacobus Johannes; Mauseth, Brynjar; Camilio, Ketil André; Vasskog, Terje & Sveinbjørnsson, Baldur [Vis alle 9 forfattere av denne artikkelen] (2021). Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer. Scientific Reports. ISSN 2045-2322. 11. doi: 10.1038/s41598-021-86239-6. Fulltekst i vitenarkiv Vis sammendrag

  Oncolytic peptides represent a novel, promising cancer treatment strategy with activity in a broad spectrum of cancer entities, including colorectal cancer (CRC). Cancer cells are killed by immunogenic cell death, causing long-lasting anticancer immune responses, a feature of particular interest in non-immunogenic CRC. Oncolytic peptides DTT-205 and DTT-304 were administered by intratumoral injection in subcutaneous tumors established from murine CRC cell lines CT26 and MC38, and complete regression was obtained in the majority of animals. When cured animals were rechallenged by splenic injection of tumor cells, 1/23 animals developed liver metastases, compared to 19/22 naïve animals. Treatment with both peptides was well tolerated, but monitoring post-injection hemodynamic parameters in rats, less extensive changes were observed with DTT-205 than DTT-304, favoring DTT-205 for future drug development. DTT-205 was subsequently shown to have strong in vitro activity in a panel of 33 cancer cell lines. In conclusion, both peptides exerted a strong inhibitory effect in two immunocompetent CRC models and induced a systemic effect preventing development of liver metastases upon splenic rechallenge. If a similar effect could be obtained in humans, these drugs would be of particular interest for combinatory treatment with immune checkpoint inhibitors in metastatic CRC.

• Chok, Aik Yong; Oliver, A; Rasheed, S; Tan, E J; Kelly, M E & Aalbers, A G J [Vis alle 53 forfattere av denne artikkelen] (2021). Perioperative management and anaesthetic considerations in pelvic exenterations using Delphi methodology: results from the PelvEx Collaborative. BJS Open. ISSN 2474-9842. 5(1). doi: 10.1093/bjsopen/zraa055. Fulltekst i vitenarkiv
• Knuth, Franziska Hanna; Adde, Ingvild Askim; Huynh, Bao Ngoc; Grøndahl, Aurora Rosvoll; Winter, René & Negård, Anne [Vis alle 15 forfattere av denne artikkelen] (2021). MRI-based automatic segmentation of rectal cancer using 2D U-Net on two independent cohorts. Acta Oncologica. ISSN 0284-186X. 61(2), s. 255–263. doi: 10.1080/0284186X.2021.2013530. Fulltekst i vitenarkiv
• Lund-Andersen, Christin; Kristensen, Annette Torgunrud; Fleten, Karianne Giller & Flatmark, Kjersti (2021). Omics analyses in peritoneal metastasis-utility in the management of peritoneal metastases from colorectal cancer and pseudomyxoma peritonei: a narrative review. Journal of Gastrointestinal Oncology (JGO). ISSN 2078-6891. 12(Supplement 1). doi: 10.21037/JGO-20-136. Fulltekst i vitenarkiv
• Andersson, Yvonne; Fleten, Karianne Giller; Abrahamsen, Torveig Weum; Reed, Wenche; Davidson, Ben & Flatmark, Kjersti (2021). Anti-Angiogenic Treatment in Pseudomyxoma Peritonei - Still a Strong Preclinical Rationale. Cancers. ISSN 2072-6694. 13:2819(11), s. 1–11. doi: 10.3390/cancers13112819. Fulltekst i vitenarkiv
• Larsen, Stein Gunnar; Goscinski, Mariusz Adam; Dueland, Svein; Steigen, Sonja Eriksson; Hofsli, Eva & Torgunrud, Annette [Vis alle 10 forfattere av denne artikkelen] (2021). Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients. British Journal of Cancer. ISSN 0007-0920. doi: 10.1038/s41416-021-01620-6. Fulltekst i vitenarkiv Vis sammendrag

  Patients with metastatic colorectal cancer (mCRC) carrying BRAF (mutBRAF) or KRAS mutation (mutKRAS) have an inferior prognosis after liver or lung surgery, whereas the prognostic role in the context of peritoneal metastasis (PM) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has been less investigated. Methods In total, 257 patients with non-appendiceal PM-CRC were included from the Norwegian National Unit for CRS-HIPEC. Results In total, 180 patients received CRS-HIPEC with Mitomycin C, 77 patients received palliative surgery only. In the CRS-HIPEC group, mutBRAF was found in 24.7%, mutKRAS 33.9% and double wild-type 41.4% without differences in survival. MSI was found in 29.3% of mutBRAF cases. Patients with mutBRAF/MSI had superior 5-year survival compared to mutBRAF with MSS (58.3% vs 25.2%, P = 0.022), and better 3-year disease-free survival (DFS) compared to mutKRAS (48.6% vs 17.2%, P = 0.049). Peritoneal Cancer Index and the number of lymph node metastasis were prognostic for OS, and the same two, location and gender prognostic for DFS in multivariate analysis. Conclusions PM-CRC with CRS-HIPEC patients has a surprisingly high proportion of mutBRAF (24.7%). Survival was similar comparing mutBRAF, mutKRAS and double wild-type cases, whereas a small subgroup with mutBRAF and MSI had better survival. Patients with mutBRAF tumours and limited PM should be considered for CRS-HIPEC.

• Flatmark, Kjersti; Torgunrud, Annette ; Fleten, Karianne G; Davidson, Ben; Juul, Hedvig Vidarsdotter & Mensali, Nadia [Vis alle 8 forfattere av denne artikkelen] (2021). Peptide vaccine targeting mutated GNAS: A potential novel treatment for pseudomyxoma peritonei. Journal for ImmunoTherapy of Cancer (JITC). 9:e003109(10), s. 1–10. doi: 10.1136/jitc-2021-003109. Fulltekst i vitenarkiv
• Dagenborg, Vegar Johansen; Marshall, Serena; Grzyb, Krzysztof; Fretland, Åsmund Avdem; Lund-Iversen, Marius & Mælandsmo, Gunhild Mari [Vis alle 10 forfattere av denne artikkelen] (2021). Low Concordance Between T-Cell Densities in Matched Primary Tumors and Liver Metastases in Microsatellite Stable Colorectal Cancer. Frontiers in Oncology. ISSN 2234-943X. 11, s. 1–9. doi: 10.3389/fonc.2021.671629. Fulltekst i vitenarkiv
• Mariathasan, Anthony Burton; Boye, Kjetil; Dueland, Svein; Flatmark, Kjersti & Larsen, Stein Gunnar (2021). Metastases in locally advanced rectal cancer undergoing curatively intended treatment. European Journal of Surgical Oncology. ISSN 0748-7983. doi: 10.1016/j.ejso.2021.04.023.
• Meltzer, Sebastian; Kristensen, Annette Torgunrud; Abrahamsson, Hanna Josefine; Solbakken, Arne Mide; Flatmark, Kjersti & Dueland, Svein [Vis alle 15 forfattere av denne artikkelen] (2021). The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer. British Journal of Cancer. ISSN 0007-0920. 125, s. 240–246. doi: 10.1038/s41416-021-01377-y. Fulltekst i vitenarkiv
• Thorgersen, Ebbe Billmann; Asvall, Jørund; Frøysnes, Ida Storhaug; Schjalm, Camilla; Larsen, Stein Gunnar & Dueland, Svein [Vis alle 10 forfattere av denne artikkelen] (2021). Increased Local Inflammatory Response to MOC31PE Immunotoxin After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Annals of Surgical Oncology. ISSN 1068-9265. doi: 10.1245/s10434-021-10022-0. Fulltekst i vitenarkiv
• Dagenborg, Vegar Johansen; Marshall, Serena Elizabeth; Grzyb, Krzysztof; Fretland, Åsmund Avdem; Lund-Iversen, Marius & Mælandsmo, Gunhild Mari [Vis alle 10 forfattere av denne artikkelen] (2020). Low concordance between T-cell densities in matched primary tumors and liver metastases in microsatellite stable colorectal cancer. Frontiers in Oncology. ISSN 2234-943X. 11.
• Flatmark, Kjersti & Mohamed, Faheez (2020). ASO Author Reflections: Estimating the Prevalence of Pseudomyxoma Peritonei in Europe Using a Novel Statistical Method. Annals of Surgical Oncology. ISSN 1068-9265. 27, s. 771–772. doi: 10.1245/s10434-020-08691-4. Fulltekst i vitenarkiv
• Dagenborg, Vegar Johansen; Marshall, Serena; Yaqub, Sheraz; Grzyb, Krzysztof; Pedersen, Kjetil Boye & Lund-Iversen, Marius [Vis alle 12 forfattere av denne artikkelen] (2020). Neoadjuvant chemotherapy is associated with a transient increase of intratumoral T-cell density in microsatellite stable colorectal liver metastases. Cancer Biology & Therapy. ISSN 1538-4047. 21(5), s. 432–440. doi: 10.1080/15384047.2020.1721252. Fulltekst i vitenarkiv
• Meltzer, Sebastian; Bjørnetrø, Tonje; Lyckander, Lars Gustav; Flatmark, Kjersti; Dueland, Svein & Samiappan, Rampradeep [Vis alle 10 forfattere av denne artikkelen] (2020). Corrigendum to “Circulating exosomal miR-141-3p and miR-375 in metastatic progression of rectal cancer” [Transl Oncol 12 (8) (2019) 1038-1044]. Translational Oncology. ISSN 1944-7124. 133(1), s. 122–124. doi: 10.1016/j.tranon.2019.09.005. Fulltekst i vitenarkiv
• Aghayan, Davit; Kazaryan, Airazat; Dagenborg, Vegar Johansen; Røsok, Bård Ingvald; Fagerland, Morten Wang & Bjørnelv, Gudrun Maria Waaler [Vis alle 10 forfattere av denne artikkelen] (2020). Long-term oncologic outcomes after laparoscopic versus open resection for colorectal liver metastasis. Annals of Internal Medicine. ISSN 0003-4819. 174(2), s. 175–182. doi: 10.7326/M20-4011.
• Fleten, Karianne Giller; Lund-Andersen, Christin; Waagene, Stein; Abrahamsen, Torveig Weum; Mørch, Ýrr Asbjørg & Pedersen, Kjetil Boye [Vis alle 8 forfattere av denne artikkelen] (2020). Experimental Treatment of Mucinous Peritoneal Metastases Using Patient-Derived Xenograft Models. Translational Oncology. ISSN 1944-7124. 13(8). doi: 10.1016/j.tranon.2020.100793. Fulltekst i vitenarkiv Vis sammendrag

  Mucinous peritoneal metastases (PM) generally respond poorly to systemic treatment, and there is a clear unmet need for new treatment strategies to improve survival and quality of life for patients with PM. In this work, the growth inhibitory effect of five drugs (oxaliplatin (OXA; 5 mg/kg), irinotecan (IRI; 60 mg/kg), cabazitaxel (CBZ; 15 or 30 mg/kg), regorafenib (REG; 10, 30 or 60 mg/kg), and capecitabine (CAP; 359 or 755 mg/kg) was investigated in three orthotopic patient-derived xenograft models that mimic mucinous PM. Drugs were administered intraperitoneally (i.p.) as monotherapy weekly for 4 weeks (OXA, IRI), as one single i.p. injection (CBZ), or orally (REG, CAP) daily 5 of 7 days per week for four weeks, and i.p. tumor growth and survival were monitored and compared between treatment groups. The i.p. administered drugs (OXA, IRI, CBZ) had the strongest growth inhibitory effect, with OXA being most efficacious, completely inhibiting tumor growth in the majority of the animals. CBZ and IRI also strongly inhibited tumor growth, but with more variation in efficacy between the models. A moderate reduction in tumor growth was observed in all models treated with REG, while CAP had little to no growth inhibitory effect. Targeted next-generation-sequencing has identified mutational profiles typically associated with PM (mutations in KRAS, GNAS, and BRAF oncogenes), supporting the representativeness of the models. The results presented in this work support the continued exploration of i.p. treatment protocols for PM, with OXA remaining and CBZ emerging as particularly interesting candidates for further studies.

• Patrick-Brown, Thale Dawn J.H.; Carr, Norman John; Swanson, David; Larsen, Stein Gunnar; Mohamed, Faheez & Flatmark, Kjersti (2020). Estimating the Prevalence of Pseudomyxoma Peritonei in Europe Using a Novel Statistical Method. Annals of Surgical Oncology. ISSN 1068-9265. 28(1), s. 252–257. doi: 10.1245/s10434-020-08655-8. Fulltekst i vitenarkiv Vis sammendrag

  Background: The determination of the incidence and prevalence of rare diseases is important for economists and health-care providers. Pseudomyxoma peritonei (PMP) is a rare, slow-growing abdominal cancer that represents a substantial burden on both patients and health-care systems. The incidence rate was previously approximated at 1-2 people per million per year; this incidence has never been challenged, and the prevalence has not been estimated. Methods: Epidemiological data from Norway and England were obtained and analysed to calculate a minimum incidence rate based on the number of patients having a first surgical intervention for PMP. A novel method was then used to determine a prevalence rate for PMP, incorporating incidence, death, and cure rates in a multi-year analysis that accounted for the increasing population of Europe over a 10-year period. Results: An incidence rate of 3.2 people per million per year was calculated, with a corresponding estimated prevalence rate of 22 people per million per year. By this calculation, 11,736 people in Europe were estimated to be living with PMP in 2018. Conclusion: Incidence and prevalence are essential tools for assessment of the financial and human cost of a disease. For rare diseases, such as PMP, the lack of accurate registries presents a particular challenge in determining such health-related statistical parameters. Based on our calculations, a significant number of people are living with PMP in Europe, underlining the need for appropriate resource allocation to ensure that adequate health-care measures are provided.

• Ree, Anne Hansen; Nygaard, Vigdis; Pedersen, Kjetil Boye; Heinrich, Daniel; Dueland, Svein & Bergheim, Inger Riise [Vis alle 25 forfattere av denne artikkelen] (2020). Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer?the MetAction study. Acta Oncologica. ISSN 0284-186X. s. 1–10. doi: 10.1080/0284186X.2020.1742377. Fulltekst i vitenarkiv
• Andersson, Yvonne; Inderberg, Else Marit ; Kvalheim, Gunnar; Herud, Morten Theodor Malmer; Engebråten, Olav & Flatmark, Kjersti [Vis alle 8 forfattere av denne artikkelen] (2019). Immune stimulatory effect of anti-EpCAM immunotoxin - improved overall survival of metastatic colorectal cancer patients. Acta Oncologica. ISSN 0284-186X. s. 1–7. doi: 10.1080/0284186X.2019.1704864.
• Lund-Andersen, Christin; Nakken, Sigve; Nygård, Ståle; Fromm, Bastian; Aasheim, Lars Birger & Davidson, Ben [Vis alle 13 forfattere av denne artikkelen] (2019). Integrative genomic analysis of peritoneal malignant mesothelioma: Understanding a case with extraordinary chemotherapy response. Cold Spring Harbor Molecular Case Studies. ISSN 2373-2873. 5:a003566(2), s. 1–15. doi: 10.1101/mcs.a003566. Fulltekst i vitenarkiv
• Fromm, Bastian; Domanska, Diana Ewa; Høye, Eirik; Ovchinnikov, Vladimir; Kang, Wenjing & Aparicio-Puerta, Ernesto [Vis alle 13 forfattere av denne artikkelen] (2019). MirGeneDB 2.0: the metazoan microRNA complement . Nucleic Acids Research (NAR). ISSN 0305-1048. 48(D1), s. D132–D141. doi: 10.1093/nar/gkz885. Fulltekst i vitenarkiv
• Bains, Simer Jit; Abrahamsson, Hanna Josefine; Flatmark, Kjersti; Dueland, Svein; Hole, Knut Håkon & Seierstad, Therese [Vis alle 9 forfattere av denne artikkelen] (2019). Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer. Cancer Immunology and Immunotherapy. ISSN 0340-7004. doi: 10.1007/s00262-019-02458-x. Fulltekst i vitenarkiv
• Meltzer, Sebastian; Bakke, Kine Mari; Rød, Karina Lund; Negård, Anne; Flatmark, Kjersti & Solbakken, Arne Mide [Vis alle 19 forfattere av denne artikkelen] (2019). Sex-related differences in primary metastatic site in rectal cancer; associated with hemodynamic factors? Clinical and Translational Radiation Oncology. ISSN 2405-6308. 21, s. 5–10. doi: 10.1016/j.ctro.2019.11.006. Fulltekst i vitenarkiv
• Sørensen, Olaf; Andersen, Anders Mikal; Larsen, Stein Gunnar; Giercksky, Karl-Erik & Flatmark, Kjersti (2019). Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of high-grade pseudomyxoma peritonei. Clinical and Experimental Metastasis. ISSN 0262-0898. 36(6), s. 511–518. doi: 10.1007/s10585-019-09991-0. Fulltekst i vitenarkiv
• Aghayan, Davit; Fretland, Åsmund Avdem; Kazaryan, Airazat M.; Sahakyan, Mushegh; Dagenborg, Vegar Johansen & Bjørnbeth, Bjørn Atle [Vis alle 9 forfattere av denne artikkelen] (2019). Laparoscopic versus open liver resection in the posterosuperior segments: a sub-group analysis from the OSLO-COMET randomized controlled trial. HPB. ISSN 1365-182X. 21(11), s. 1485–1490. doi: 10.1016/j.hpb.2019.03.358. Fulltekst i vitenarkiv
• Flørenes, Vivi Ann; Flem-Karlsen, Karine; McFadden, Erin; Bergheim, Inger Riise; Nygaard, Vigdis & Nygård, Vegard Mokleiv [Vis alle 17 forfattere av denne artikkelen] (2019). A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases. Translational Oncology. ISSN 1944-7124. 12(7), s. 951–958. doi: 10.1016/j.tranon.2019.04.001. Fulltekst i vitenarkiv
• Ree, Anne Hansen; Nygaard, Vigdis; Russnes, Hege Elisabeth Giercksky; Heinrich, Daniel; Nygaard, Vegard & Johansen, Christin [Vis alle 13 forfattere av denne artikkelen] (2019). Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain. Cancer immunology research. ISSN 2326-6066. 7(5), s. 701–706. doi: 10.1158/2326-6066.CIR-18-0777. Fulltekst i vitenarkiv
• Frøysnes, Ida Storhaug; Andersson, Yvonne; Larsen, Stein Gunnar; Davidson, Ben; Øien, Janne-Merete & Julsrud, Lars [Vis alle 9 forfattere av denne artikkelen] (2019). ImmunoPeCa trial: Long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis. European Journal of Surgical Oncology. ISSN 0748-7983. s. 1–5. doi: 10.1016/j.ejso.2019.04.014. Fulltekst i vitenarkiv
• Abrahamsson, Hanna Josefine; Porojnicu, Alina Carmen; Lindstrøm, Jonas Christoffer; Dueland, Svein; Flatmark, Kjersti & Hole, Knut Håkon [Vis alle 11 forfattere av denne artikkelen] (2019). High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer. BMC Cancer. ISSN 1471-2407. 19(1). doi: 10.1186/s12885-019-5724-z. Fulltekst i vitenarkiv
• Meltzer, Sebastian; Bjørnetrø, Tonje; Lyckander, Lars Gustav; Flatmark, Kjersti; Dueland, Svein & Samiappan, Rampradeep [Vis alle 10 forfattere av denne artikkelen] (2019). Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer. Translational Oncology. ISSN 1944-7124. 12(8), s. 1038–1044. doi: 10.1016/j.tranon.2019.04.014. Fulltekst i vitenarkiv
• Bousquet, Paula; Meltzer, Sebastian; Sønstevold, Linda; Esbensen, Qin Ying; Dueland, Svein & Flatmark, Kjersti [Vis alle 12 forfattere av denne artikkelen] (2018). Markers of mitochondrial metabolism in tumor hypoxia, systemic inflammation, and adverse outcome of rectal cancer. Translational Oncology. ISSN 1944-7124. 12(1), s. 76–83. doi: 10.1016/j.tranon.2018.09.010. Fulltekst i vitenarkiv
• Fusser, Markus; Øverbye, Anders; Pandya, Abhilash D.; Mørch, Ýrr Asbjørg; Borgos, Sven Even F. & Kildal, Wanja [Vis alle 16 forfattere av denne artikkelen] (2018). Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft. Journal of Controlled Release. ISSN 0168-3659. 293, s. 183–192. doi: 10.1016/j.jconrel.2018.11.029. Fulltekst i vitenarkiv
• Mariathasan, Anthony Burton; Pedersen, Kjetil Boye; Giercksky, Karl-Erik; Brennhovd, Bjørn; Gullestad, Hans Petter & Emblemsvåg, Hanne-Line [Vis alle 10 forfattere av denne artikkelen] (2018). Beyond total mesorectal excision in locally advanced rectal cancer with organ or pelvic side-wall involvement. European Journal of Surgical Oncology. ISSN 0748-7983. 44(8), s. 1226–1232. doi: 10.1016/j.ejso.2018.03.029.
• Spasojevic, Milan; Mariathasan, Anthony Burton; Goscinski, Mariusz Adam; Thorgersen, Ebbe Billmann; Solbakken, Arne Mide & Gullestad, Hans Petter [Vis alle 9 forfattere av denne artikkelen] (2018). Vertical Rectus Abdominis Musculocutaneous Flap Repair Improves Perineal Wound Healing after Abdominoperineal Resection for Irradiated Locally Advanced Rectal Cancer. Annals of Surgical Oncology. ISSN 1068-9265. 25(5), s. 1357–1365. doi: 10.1245/s10434-018-6363-3.
• Kalanxhi, Ert; Meltzer, Sebastian; Schou, Jakob Vasehus; Larsen, Finn Ole; Dueland, Svein & Flatmark, Kjersti [Vis alle 12 forfattere av denne artikkelen] (2018). Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer. British Journal of Cancer. ISSN 0007-0920. 118(10), s. 1322–1328. doi: 10.1038/s41416-018-0085-y. Fulltekst i vitenarkiv
• Mikalsen, Stine Gyland; Mikalsen, Lars Tore G; Sandvik, Joe Alexander; Aarnes, Eva-Katrine; Fenne, Siri & Flatmark, Kjersti [Vis alle 9 forfattere av denne artikkelen] (2018). Low dose-rate irradiation with [3H]-labelled valine to selectively target hypoxic cells in a human colorectal cancer xenograft model. Acta Oncologica. ISSN 0284-186X. 57(9), s. 1216–1224. doi: 10.1080/0284186X.2018.1457223.
• Fretland, Åsmund Avdem; Dagenborg, Vegar Johansen; Bjørnelv, Gudrun Maria Waaler; Kazaryan, Airazat M.; Kristiansen, Ronny & Fagerland, Morten [Vis alle 17 forfattere av denne artikkelen] (2018). Laparoscopic Versus Open Resection for Colorectal Liver Metastases: The OSLO-COMET Randomized Controlled Trial . Annals of Surgery. ISSN 0003-4932. 267(2), s. 199–207. doi: 10.1097/SLA.0000000000002353. Fulltekst i vitenarkiv Vis sammendrag

  Objective: To perform the first randomized controlled trial to compare laparoscopic and open liver resection. Summary Background Data: Laparoscopic liver resection is increasingly used for the surgical treatment of liver tumors.However, high-level evidence to conclude that laparoscopic liver resection is superior to open liver resection is lacking. Methods: Explanatory, assessor-blinded, single center, randomized superiority trial recruiting patients from Oslo University Hospital, Oslo, Norway from February 2012 to January 2016. A total of 280 patients with resectable liver metastases from colorectal cancer were randomly assigned to undergo laparoscopic (n ¼ 133) or open (n ¼ 147) parenchyma-sparing liver resection. The primary outcome was postoperative complications within 30 days (Accordion grade 2 or higher). Secondary outcomes included cost-effectiveness, postoperative hospital stay, blood loss, operation time, and resection margins. Results: The postoperative complication rate was 19% in the laparoscopicsurgery group and 31% in the open-surgery group (12 percentage points difference [95% confidence interval 1.67–21.8; P ¼ 0.021]). The postoperative hospital stay was shorter for laparoscopic surgery (53 vs 96 hours, P < 0.001), whereas there were no differences in blood loss, operation time, and resection margins. Mortality at 90 days did not differ significantly from the laparoscopic group (0 patients) to the open group (1 patient). In a 4-month perspective, the costs were equal, whereas patients in the laparoscopicsurgery group gained 0.011 quality-adjusted life years compared to patients in the open-surgery group (P ¼ 0.001). Conclusions: In patients undergoing parenchyma-sparing liver resection for colorectal metastases, laparoscopic surgery was associated with significantly less postoperative complications compared to open surgery. Laparoscopic resection was cost-effective compared to open resection with a 67% probability. The rate of free resection margins was the same in both groups. Our results support the continued implementation of laparoscopic liver resection. Keywords: colorectal liver metastases, cost and cost analysis, hepatectomy, laparoscopic, laparoscopy, liver resection, minimally invasive surgery, parenchyma-sparing liver surgery, randomized clinical trial, randomized controlled trial

• Graudenzi, Alex; Cava, Claudia; Bertoli, Gloria; Fromm, Bastian; Flatmark, Kjersti & Mauri, Giancarlo [Vis alle 7 forfattere av denne artikkelen] (2017). Pathway-based classification of breast cancer subtypes. Frontiers in Bioscience. ISSN 1093-9946. 22(10), s. 1697–1712.
• Andersson, Yvonne; Ihler, Synne; Davidson, Ben; Dørum, Anne; Fleten, Karianne Giller & Fodstad, Øystein [Vis alle 7 forfattere av denne artikkelen] (2017). MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer. OncoTarget. ISSN 1949-2553. 8(37), s. 61800–61809. doi: 10.18632/oncotarget.18694.
• Karlsen, Karine Flem; Tekle, Christina; Andersson, Yvonne; Flatmark, Kjersti; Fodstad, Øystein & Nunes-Xavier, Caroline Elisabeth (2017). Immunoregulatory protein B7-H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells. Pigment Cell & Melanoma Research. ISSN 1755-1471. 30(5), s. 467–476. doi: 10.1111/pcmr.12599. Fulltekst i vitenarkiv
• Østrup, Olga; Dagenborg, Vegar Johansen; Rødland, Einar Andreas; Skarpeteig, Veronica ; Silwal-Pandit, Laxmi & Grzyb, Krzysztof [Vis alle 14 forfattere av denne artikkelen] (2017). Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases. OncoTarget. ISSN 1949-2553. 8(44), s. 76290–76304. doi: 10.18632/oncotarget.19350. Fulltekst i vitenarkiv
• Øverbye, Anders; Holsæter, Ann Mari; Fusser, Markus; Skalko-Basnet, Natasa; Iversen, Tore Geir & Torgersen, Maria Lyngaas [Vis alle 12 forfattere av denne artikkelen] (2017). Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide. OncoTarget. ISSN 1949-2553. 8(44), s. 76921–76934. doi: 10.18632/oncotarget.20217. Fulltekst i vitenarkiv
• Bakke, Kine Mari; Hole, Knut Håkon; Dueland, Svein; Kotanska-Grøholt, Krystyna; Flatmark, Kjersti & Ree, Anne Hansen [Vis alle 8 forfattere av denne artikkelen] (2017). Diffusion-weighted magnetic resonance imaging of rectal cancer: tumour volume and perfusion fraction predict chemoradiotherapy response and survival. Acta Oncologica. ISSN 0284-186X. 56(6), s. 813–818. doi: 10.1080/0284186X.2017.1287951. Fulltekst i vitenarkiv
• Frøysnes, Ida Storhaug; Andersson, Yvonne; Larsen, Stein Gunnar; Davidson, Ben; Øien, Janne-Merete & Olsen, Kari Hauge [Vis alle 11 forfattere av denne artikkelen] (2017). Novel treatment with intraperitoneal MOC31PE immunotoxin in colorectal peritoneal metastasis: results from the ImmunoPeCa Phase 1 Trial. Annals of Surgical Oncology. ISSN 1068-9265. 24(7), s. 1916–1922. doi: 10.1245/s10434-017-5814-6.
• Ree, Anne Hansen; Russnes, Hege Elisabeth Giercksky; Heinrich, Daniel; Dueland, Svein; Pedersen, Kjetil Boye & Nygaard, Vigdis [Vis alle 34 forfattere av denne artikkelen] (2017). Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate. ESMO Open. ISSN 2059-7029. 2(2), s. 1–10. doi: 10.1136/esmoopen-2017-000158. Fulltekst i vitenarkiv
• Kalanxhi, Ert; Risberg, Karianne; Barua, Imon Shoumitra; Dueland, Svein; Waagene, Stein & Andersen, Solveig Norheim [Vis alle 11 forfattere av denne artikkelen] (2017). Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy. Cancer research and treatment : official journal of Korean Cancer Association. ISSN 1598-2998. 49(2), s. 374–386. doi: 10.4143/crt.2016.080. Fulltekst i vitenarkiv
• Fleten, Karianne Giller; Bakke, Kine Mari; Mælandsmo, Gunhild; Abildgaard, Andreas; Redalen, Kathrine Røe & Flatmark, Kjersti (2017). Use of non-invasive imaging to monitor response to aflibercept treatment in murine models of colorectal cancer liver metastases. Clinical and Experimental Metastasis. ISSN 0262-0898. 34(1), s. 51–62. doi: 10.1007/s10585-016-9829-3.
• Thorgersen, Ebbe Billmann; Goscinski, Mariusz Adam; Spasojevic, Milan; Solbakken, Arne Mide; Mariathasan, Anthony Burton & Pedersen, Kjetil Boye [Vis alle 8 forfattere av denne artikkelen] (2017). Deep Pelvic Surgical Site Infection After Radiotherapy and Surgery for Locally Advanced Rectal Cancer. Annals of Surgical Oncology. ISSN 1068-9265. 24(3), s. 721–728. doi: 10.1245/s10434-016-5621-5.
• Frøysnes, Ida Storhaug; Larsen, Stein Gunnar; Spasojevic, Milan; Dueland, Svein & Flatmark, Kjersti (2016). Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastasis in Norway: Prognostic Factors and Oncologic Outcome in a National Patient Cohort. Journal of Surgical Oncology. ISSN 0022-4790. 114(2), s. 222–227. doi: 10.1002/jso.24290.
• Goscinski, Mariusz Adam; Hole, Knut Håkon; Tønne, Elin; Ryder, Truls; Kotanska-Grøholt, Krystyna & Flatmark, Kjersti (2016). Fibromatosis in vertical rectus abdominis myocutaneous flap imitating tumor recurrence after surgery for locally advanced rectal cancer: Case report. World Journal of Surgical Oncology (WJSO). ISSN 1477-7819. 14. doi: 10.1186/s12957-016-0818-4.
• Pedersen, Kjetil Boye; Jacob, Havjin; Frikstad, Kari-Anne; Nesland, Jahn M; Mælandsmo, Gunhild & Dahl, Olav [Vis alle 8 forfattere av denne artikkelen] (2016). Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy. Cancer Medicine. ISSN 2045-7634. 5(8), s. 1840–1849. doi: 10.1002/cam4.766. Fulltekst i vitenarkiv
• Dueland, Svein; Ree, Anne Hansen; Kotanska-Grøholt, Krystyna; Sælen, Marie Grøn; Folkvord, Sigurd & Hole, Knut Håkon [Vis alle 12 forfattere av denne artikkelen] (2016). Oxaliplatin-containing Preoperative Therapy in Locally Advanced Rectal Cancer: Local Response, Toxicity and Long-term Outcome. Clinical Oncology. ISSN 0936-6555. 28(8), s. 532–539. doi: 10.1016/j.clon.2016.01.014.
• Flatmark, Kjersti; Sælen, Marie Grøn; Hole, Knut Håkon; Abrahamsen, Torveig Weum; Fleten, Karianne Giller & Hektoen, Helga [Vis alle 10 forfattere av denne artikkelen] (2016). Individual tumor volume responses to short-course oxaliplatin containing induction chemotherapy in locally advanced rectal cancer – Targeting the tumor for radiation sensitivity? Radiotherapy and Oncology. ISSN 0167-8140. 119(3), s. 505–511. doi: 10.1016/j.radonc.2016.02.020. Vis sammendrag

  Background Neoadjuvant treatment of locally advanced rectal cancer (LARC) involves chemoradiotherapy (CRT), which may cause significant toxicity, and the potential role and sequential placement of neoadjuvant chemotherapy (NACT) relative to CRT is under debate. Patients and methods In a non-randomized study of 72 LARC patients, short-course oxaliplatin-containing NACT was administered prior to CRT. Tumor volumes were calculated from magnetic resonance images before and after NACT, and four weeks after CRT, and associations between tumor volume responses and outcome were analyzed. Additionally, the impact of oxaliplatin exposure on radiosensitivity was examined in colorectal carcinoma cell lines. Results All tumors except one responded to NACT, with better responses in T3 than T4 cases, and 69/72 patients obtained additional tumor volume reduction after subsequent CRT. However, no associations were found between tumor volume reduction and long-term outcome. Of note, oxaliplatin-resistant cells were significantly more radiosensitive than the oxaliplatin-sensitive counterparts. Conclusions Oxaliplatin-containing NACT led to substantial tumor volume reduction with particularly good responses in T3 cases. NACT did not impede subsequent CRT response, and experimental results rather suggested enhanced radiosensitivity in oxaliplatin-exposed cells, encouraging studies to explore the administration of NACT prior to CRT. Data are still lacking to support omitting radiation in LARC management.

• Jonsson, Marte; Ragnum, Harald Bull; Halle, Cathinka Lønning; Yeramian, Andree; Clancy, Trevor & Frikstad, Kari-Anne [Vis alle 12 forfattere av denne artikkelen] (2016). Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition. British Journal of Cancer. ISSN 0007-0920. 115(8), s. 929–939. doi: 10.1038/bjc.2016.278.
• Flatmark, Kjersti; Høye, Erik Ulvolden & Fromm, Bastian (2016). microRNAs as cancer biomarkers. Scandinavian Journal of Clinical and Laboratory Investigation. ISSN 0036-5513. 76, s. S80–S83. doi: 10.1080/00365513.2016.1210330.
• Kalanxhi, Ert; Hektoen, Helga; Meltzer, Sebastian; Dueland, Svein; Flatmark, Kjersti & Ree, Anne Hansen (2016). Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening. BMC Cancer. ISSN 1471-2407. 16:536. doi: 10.1186/s12885-016-2601-x.
• Meltzer, Sebastian; Kalanxhi, Ert; Hektoen, Helga; Dueland, Svein; Flatmark, Kjersti & Redalen, Kathrine Røe [Vis alle 7 forfattere av denne artikkelen] (2016). Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer. OncoTarget. ISSN 1949-2553. 7(23), s. 34907–34917. doi: 10.18632/oncotarget.8995. Vis sammendrag

  In colorectal cancer, immune effectors may be determinative for disease outcome. Following curatively intended combined-modality therapy in locally advanced rectal cancer metastatic disease still remains a dominant cause of failure. Here, we investigated whether circulating immune factors might correlate with outcome. An antibody array was applied to assay changes of approximately 500 proteins in serial serum samples collected from patients during oxaliplatin-containing induction chemotherapy and sequential chemoradiotherapy before final pelvic surgery. Array data was analyzed by the Significance Analysis of Microarrays software and indicated significant alterations in serum osteoprotegerin (TNFRSF11B) during the treatment course, which were confirmed by osteoprotegerin measures using a single-parameter immunoassay. Patients experiencing increase in circulating osteoprotegerin during the chemotherapy had significantly better 5-year progression-free survival than those without increase (78% versus 48%; P = 0.009 by log-rank test). Hence, systemic release of this soluble tumor necrosis factor decoy receptor following the induction phase of neoadjuvant therapy was associated with favorable long-term outcome in patients given curatively intended chemoradiotherapy and surgery but with metastatic disease as the main adverse event. This finding suggests that osteoprotegerin may mediate or reflect systemic anti-tumor immunity invoked by combined-modality therapy in locally advanced rectal cancer.

• Egeland, Eivind Valen; Flatmark, Kjersti; Nesland, Jahn M; Flørenes, Vivi Ann; Mælandsmo, Gunhild & Pedersen, Kjetil Boye (2016). Expression and clinical significance of Wee1 in colorectal cancer. Tumour Biology. ISSN 1010-4283. 37(9), s. 12133–12140. doi: 10.1007/s13277-016-5081-3.
• Redalen, Kathrine Røe; Sitter, Beathe; Bathen, Tone Frost; Kotanska-Grøholt, Krystyna; Hole, Knut Håkon & Dueland, Svein [Vis alle 9 forfattere av denne artikkelen] (2016). High tumor glycine concentration is an adverse prognostic factor in locally advanced rectal cancer. Radiotherapy and Oncology. ISSN 0167-8140. 118(2), s. 393–398. doi: 10.1016/j.radonc.2015.11.031.
• Fromm, Bastian; Billipp, Tyler; Peck, Liam E.; Johansen, Morten; Tarver, James E. & King, Benjamin L. [Vis alle 11 forfattere av denne artikkelen] (2015). A Uniform System for the Annotation of Vertebrate microRNA Genes and the Evolution of the Human microRNAome. Annual Review of Genetics. ISSN 0066-4197. 49, s. 213–242. doi: 10.1146/annurev-genet-120213-092023.

Se alle arbeider i Cristin

• Fleten, Karianne Giller; Flatmark, Kjersti; Åslund, Karl Olof Andreas; Snipstad, Linn Sofie Rudbæk; Borgos, Sven Even F. & Mørch, Yrr Asbjörg (2022). The in vivo fate of poly(alkyl cyanoacrylate) (PACA) nanoparticles and their payload.
• Meltzer, Sebastian; Negård, Anne; Hamre, Hanne Mari; Kersten, Christian; Hofsli, Eva & Guren, Marianne Grønlie [Vis alle 9 forfattere av denne artikkelen] (2022). Early radiologic signal of nivolumab responsiveness after short-course oxaliplatin-based chemotherapy in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).
• Hyldbakk, Astrid; Fleten, Karianne Giller; Flatmark, Kjersti; Åslund, Andreas; Snipstad, Sofie & Borgos, Sven Even F. [Vis alle 7 forfattere av denne artikkelen] (2022). The in vivo fate of poly(alkyl cyanoacrylate) (PACA) nanoparticles and their payload.
• Hyldbakk, Astrid; Fleten, Karianne Giller; Snipstad, Sofie; Åslund, Andreas; Davies, Ruth Catharina de Lange & Flatmark, Kjersti [Vis alle 7 forfattere av denne artikkelen] (2022). ENPERITO: polymeric nanoparticles for treatment of peritoneal metastases - a toxicity, biodstribution and efficacy study.
• Fusser, Markus; Øverbye, Anders; Pandya, Abhilash D.; Mørch, Ýrr Asbjørg; Borgos, Sven Even F. & Kildal, Wanja [Vis alle 16 forfattere av denne artikkelen] (2022). Corrigendum to “Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft”, [Journal of Control Release, 293 (2019) 183–192, (Journal of Control Release, (2019) 293(183-192) (S0168365918306928), (10.1016/j.jconrel.2018.11.029)). Journal of Controlled Release. ISSN 0168-3659. 349. doi: 10.1016/j.jconrel.2022.06.040.
• Ree, Anne Hansen; Hamre, Hanne Mari; Kersten, Christian; Hofsli, Eva; Guren, Marianne Grønlie & Sørbye, Halfdan [Vis alle 10 forfattere av denne artikkelen] (2021). Repeat sequential oxaliplatin-based chemotherapy (FLOX) and nivolumab versus FLOX alone as first-line treatment of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC): Initial results from the randomized METIMMOX study.
• Sørensen, Olaf; Andersen, Anders Mikal; Larsen, Stein Gunnar; Giercksky, Karl-Erik & Flatmark, Kjersti (2021). Correction to: Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of highgrade pseudomyxoma peritonei (Clinical & Experimental Metastasis, (2019), 36, 6, (511-518), 10.1007/s10585-019-09991-0). Clinical and Experimental Metastasis. ISSN 0262-0898. 38(2). doi: 10.1007/s10585-021-10084-0.
• Knuth, Franziska Hanna; Adde, Ingvild Askim; Huynh, Bao Ngoc; Grøndahl, Aurora Rosvoll; Winter, René & Negård, Anne [Vis alle 15 forfattere av denne artikkelen] (2021). MRI-based automatic segmentation of rectal cancer using 2D U-Net on two independent cohorts.
• Aghayan, Davit; Dagenborg, Vegar Johansen; Grzyb, Krzysztof; Fretland, Åsmund Avdem; Kazaryan, Airazat & Yaqub, Sheraz [Vis alle 8 forfattere av denne artikkelen] (2021). Histopathologic Growth Patterns of Colorectal Liver Metastases for Predicting Survival after Liver Resection: Data from the OSLO-COMET RCT. HPB. ISSN 1365-182X. doi: 10.1016/j.hpb.2020.11.040.
• Hyldbakk, Astrid; Fleten, Karianne Giller; Snipstad, Sofie; Åslund, Andreas; Folkesson, Evelina & Flatmark, Kjersti [Vis alle 7 forfattere av denne artikkelen] (2021). ENPERITO: Polymeric nanoparticles for treatment of peritoneal metastases.
• Thorgersen, Ebbe Billmann & Flatmark, Kjersti (2021). ASO Author Reflections: The Peritoneum is an Active Immunological Compartment. Annals of Surgical Oncology. ISSN 1068-9265. s. 1–2. doi: 10.1245/s10434-021-10036-8.
• Fromm, Bastian; Domanska, Diana; Høye, Eirik; Ovchinnikov, Vladimir; Kang, Wenjing & Aparicio-Puerta, Ernesto [Vis alle 13 forfattere av denne artikkelen] (2020). Erratum: MirGeneDB 2.0: The metazoan microRNA complement (Nucleic Acids Research (2019) DOI: 10.1093/nar/gkz885). Nucleic Acids Research (NAR). ISSN 0305-1048. 48(1). doi: 10.1093/nar/gkz1016.
• Meltzer, Sebastian; Bakke, Kine Mari; Lund Rød, Karina; Dueland, Svein; Flatmark, Kjersti & Kristensen, Annette Torgunrud [Vis alle 12 forfattere av denne artikkelen] (2019). Gender disparities in outcome after neoadjuvant chemoradiotherapy for locally advanced rectal cancer are associated with hemodynamic differences.
• Meltzer, Sebastian; Redalen, Kathrine; Dueland, Svein; Kristensen, Annette Torgunrud; Solbakken, Arne Mide & Flatmark, Kjersti [Vis alle 7 forfattere av denne artikkelen] (2019). Circulating angiogenic factors predict metastatic liver progression in rectal cancer patients given curative-intent oxaliplatin-containing neoadjuvant therapy.
• Bousquet, Paula; Meltzer, Sebastian; Sønstevold, Linda; Esbensen, Qin Ying; Lyckander, Lars Gustav & Dueland, Svein [Vis alle 10 forfattere av denne artikkelen] (2017). Reactive oxygen species (ROS) and mitochondrial DNA (mtDNA) damage in tumor hypoxia, poor radiotherapy response, and metastatic progression of rectal cancer. Cancer Research. ISSN 0008-5472. 77, s. 1782–1782. doi: 10.1158/1538-7445.AM2017-1782.
• Bakke, Kine Mari; Hole, Knut Håkon; Dueland, Svein; Grøholt, Krystyna Kotanska; Ree, Anne Hansen & Flatmark, Kjersti [Vis alle 8 forfattere av denne artikkelen] (2017). Diffusion-weighted MRI of rectal cancer: baseline tumour perfusion fraction predicts chemoradiotherapy response and survival.
• Goscinski, Mariusz Adam; Hole, Knut Håkon; Tønne, Elin; Ryder, Truls; Kotanska-Grøholt, Krystyna & Flatmark, Kjersti (2016). Fibromatosis in vertical rectus abdominis myocutaneous flap imitating tumor recurrence after surgery for locally advanced rectal cancer: case report. World Journal of Surgical Oncology (WJSO). ISSN 1477-7819. 14(63). doi: 10.1186/s12957-016-0818-4.
• Fleten, Karianne Giller; Bakke, Kine Mari; Abildgaard, Andreas; Mælandsmo, Gunhild; Redalen, Kathrine Røe & Flatmark, Kjersti (2016). Diffusion-weighted MRI can predict response to aflibercept in in vivo models.
• Bakke, Kine Mari; Seierstad, Therese; Hole, Knut Håkon; Dueland, Svein; Flatmark, Kjersti & Ree, Anne Hansen [Vis alle 7 forfattere av denne artikkelen] (2016). Histogram analysis of ADCs from DWMRI predicts tumour response and survival for rectal cancer.
• Redalen, Kathrine Røe; Sitter, Beathe; Bathen, Tone Frost; Grøholt, Krystyna Kotanska; Hole, Knut Håkon & Dueland, Svein [Vis alle 9 forfattere av denne artikkelen] (2016). High tumour glycine concentration – an adverse prognostic factor in locally advanced rectal cancer.
• Bakke, Kine Mari; Hole, Knut Håkon; Dueland, Svein; Flatmark, Kjersti; Ree, Anne Hansen & Seierstad, Therese [Vis alle 7 forfattere av denne artikkelen] (2016). Tumour perfusion estimated from diffusion-weighted MRI of rectal cancer – an indirect marker of tumour hypoxia?
• Meltzer, Sebastian; Kalanxhi, Ert; Dueland, Svein; Flatmark, Kjersti; Redalen, Kathrine Røe & Ree, Anne Hansen (2016). Oxaliplatin-induced immune factors and long-term disease control in rectal cancer - a reflection of immunogenic tumor cell death?
• Meltzer, Sebastian; Kalanxhi, Ert; Hektoen, Helga; Dueland, Svein; Flatmark, Kjersti & Redalen, Kathrine Røe [Vis alle 7 forfattere av denne artikkelen] (2015). Circulating tumor necrosis factor receptor (TNFR) proteins in systemic disease outcome to combined-modality radiotherapy in rectal cancer.
• Hektoen, Helga; Ree, Anne Hansen; Redalen, Kathrine Røe & Flatmark, Kjersti (2015). Translational studies of microenvironmental factors in rectal cancer with emphasis on tumor hypoxia. Akademika forlag. ISSN 978-82-8333-077-9.

Se alle arbeider i Cristin